Chronic constipation Medical Services in China

Chronic constipation is a common functional gastrointestinal disorder characterized by persistent difficulty in passing stools, infrequent bowel movements (typically fewer than three per week), and/or a sensation of incomplete evacuation, straining, or rectal blockage—lasting for at least six months, with symptoms present for the last three months. It is not attributable to structural, metabolic, or systemic disease, nor solely explained by medication use or inadequate fiber intake. Pathophysiologically, chronic constipation arises from complex interactions among colonic motility dysfunction (e.g., slow-transit constipation), pelvic floor dyssynergia (impaired coordination of abdominal and pelvic floor muscles during defecation), visceral hypersensitivity, altered gut microbiota composition, and dysregulation of the brain-gut axis. Neurotransmitter imbalances—including reduced serotonin (5-HT) signaling and abnormal enteric nervous system activity—also contribute significantly. Epidemiologically, chronic constipation affects approximately 12–19% of the global adult population, with higher prevalence in women (up to 2.5× more common than in men), older adults (>60 years), and individuals with sedentary lifestyles. In China, community-based studies estimate prevalence at 6–15%, rising sharply with age and urbanization. Key modifiable risk factors include low dietary fiber intake (<20 g/day), chronic dehydration, physical inactivity, excessive use of laxatives (especially stimulant types), opioid or anticholinergic medications, and psychological stressors such as anxiety and depression. Non-modifiable risks include female sex, advancing age, and comorbid conditions like irritable bowel syndrome (IBS-C), diabetes mellitus, hypothyroidism, and Parkinson’s disease. Beyond physiological discomfort, chronic constipation profoundly impairs quality of life: patients report increased fatigue, abdominal bloating and pain, reduced work productivity, social withdrawal, sleep disturbances, and heightened risk of anxiety and depressive disorders. Complications may include hemorrhoids, anal fissures, fecal impaction, and overflow incontinence—particularly in frail elderly populations. Early diagnosis requires careful clinical evaluation, including Rome IV criteria assessment, exclusion of secondary causes (e.g., colonoscopy for red-flag symptoms), and, when indicated, anorectal manometry or colonic transit studies. Patient education on lifestyle modification—fiber optimization (25–35 g/day), timed toilet habits, adequate hydration (1.5–2 L/day), and daily physical activity—is foundational. Multidisciplinary management involving gastroenterologists, dietitians, and pelvic floor physiotherapists improves long-term outcomes and reduces relapse.

Chronic constipation, defined as persistent or recurrent symptoms of difficult, infrequent, or incomplete defecation lasting ≥12 weeks within the preceding 12 months (Rome IV criteria), is a prevalent functional gastrointestinal disorder affecting approximately 14% of adults globally. In gastroenterology practice, management prioritizes symptom relief, restoration of physiological bowel habits, and prevention of complications such as fecal impaction, rectal prolapse, or megarectum. A stepwise, patient-centered approach—integrating conservative measures, pharmacotherapy, and, rarely, surgical intervention—is standard in digestive medicine departments worldwide, including specialized centers in China.

Conservative treatment forms the cornerstone of initial management and should be sustained for at least 8–12 weeks before reassessing efficacy. Dietary modification emphasizes gradual increase in non-fermentable, insoluble fiber (e.g., wheat bran, psyllium husk) to 25–30 g/day, coupled with adequate hydration (1.5–2 L of water daily) to prevent stool hardening. Behavioral interventions include scheduled toilet time—ideally 15–20 minutes after breakfast—to leverage the gastrocolic reflex—and proper positioning (squatting or footstool-assisted forward-leaning posture) to optimize pelvic floor relaxation and anorectal angle. Biofeedback therapy is strongly recommended for patients with dyssynergic defecation, demonstrated by abnormal electromyographic patterns during simulated evacuation; evidence shows ≥70% symptom improvement after 4–6 weekly sessions conducted by trained physiotherapists or gastroenterology nurses. Physical activity—such as brisk walking ≥30 minutes five times weekly—enhances colonic transit via autonomic modulation and reduces visceral adiposity-related motilin suppression.

When conservative strategies fail, pharmacologic therapy is initiated based on pathophysiology and safety profile. First-line agents include osmotic laxatives: polyethylene glycol 3350 (17 g/day, titrated to effect) remains the gold-standard due to its electrolyte-neutral action, minimal systemic absorption, and favorable long-term safety. Second-line options include sodium picosulfate (a stimulant prodrug activated by colonic flora) and lactulose (0.5–2 g TID), though the latter may cause bloating and flatulence. For refractory cases with documented slow-transit constipation, newer agents are increasingly utilized: prucalopride (2 mg daily), a highly selective 5-HT4 receptor agonist, accelerates colonic transit and improves spontaneous bowel movement frequency in >60% of patients after 4 weeks. Lubiprostone (24 mcg BID), a chloride channel activator, enhances intestinal fluid secretion and is particularly effective in opioid-induced constipation and female-predominant chronic constipation. Linaclotide (290 mcg daily) and plecanatide (3 mg daily), guanylate cyclase-C agonists, promote fluid secretion and reduce visceral hypersensitivity—both demonstrate robust efficacy in clinical trials and are approved in China’s National Reimbursement Drug List since 2021. All medications require individualized dosing, monitoring for electrolyte shifts (especially in elderly or renally impaired patients), and avoidance of chronic stimulant laxative overuse (e.g., senna, bisacodyl), which risks melanosis coli and potential enteric neuropathy.

Surgical intervention is reserved for <5% of patients with severe, medically refractory constipation and objective evidence of pathology. Indications include confirmed colonic inertia (transit study showing >70% radiopaque markers retained at 120 hours), outlet obstruction unresponsive to biofeedback, or structural anomalies (e.g., rectocele >3 cm with enterocele, internal rectal intussusception). Procedures performed in high-volume Chinese centers include laparoscopic total colectomy with ileorectal anastomosis—associated with 65–75% long-term success but carrying risks of postoperative diarrhea (20–30%), small-bowel obstruction (5–8%), and reduced quality-of-life scores in up to 25% due to altered bowel control. For outlet dysfunction, transanal minimally invasive surgery (TAMIS) for rectocele repair or stapled transanal rectal resection (STARR) may be considered, though STARR carries higher complication rates (e.g., bleeding, stenosis, de novo incontinence) and is now used selectively following rigorous preoperative pelvic floor MRI and dynamic defecography. Surgery is never undertaken without multidisciplinary consensus involving gastroenterologists, colorectal surgeons, and pelvic floor specialists.

China offers distinct advantages in chronic constipation management. First, integrated Traditional Chinese Medicine (TCM) modalities—such as acupuncture at ST25 (Tianshu) and CV6 (Qihai), and herbal formulas like Maziren Wan (Apricot Kernel Seed Pill)—are routinely combined with Western protocols in Class III-A hospitals, with randomized trials demonstrating synergistic improvement in colonic transit time and symptom scores. Second, nationwide digital health infrastructure enables remote symptom tracking via AI-powered apps linked to electronic medical records, facilitating real-time medication adherence monitoring and timely teleconsultations. Third, China’s centralized drug procurement policy has reduced costs of prucalopride and linaclotide by >40%, improving accessibility. Finally, standardized national guidelines (CMA 2023 Consensus on Functional Constipation) ensure uniform diagnostic workup—including validated questionnaires (PAC-SYM, PAC-QOL), colonic transit scintigraphy, and high-resolution anorectal manometry—across tiered healthcare facilities.

Recovery and long-term maintenance emphasize sustainability. Patients should maintain fiber intake and hydration indefinitely, avoid prolonged straining, and continue scheduled toileting even after symptom resolution. Follow-up visits every 3–6 months allow reassessment of medication need, adjustment of lifestyle strategies, and screening for red-flag symptoms (e.g., unintentional weight loss, rectal bleeding, iron-deficiency anemia) that warrant colonoscopy. Psychological support is integral: anxiety and depression correlate strongly with symptom severity, and cognitive behavioral therapy (CBT) delivered by hospital-based psychologists improves treatment adherence and reduces healthcare utilization. Importantly, patients must understand that chronic constipation is a relapsing condition—not cured but effectively managed—requiring active partnership with their gastroenterology team. With comprehensive, evidence-based care, >85% of patients achieve meaningful symptom reduction and improved quality of life.